



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

AARTI DRUGS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th September, 2012

Rs. in Lacs except for share data

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Financial Year Ended
		30th Sept, 2012	30th June, 2012	30th Sept, 2011	30th Sept, 2012	30th Sept, 2011	31st Mar, 2012
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Income from Operations	23,266	20,388	15,348	43,655	31,037	69,918
	(a) Gross Sales / Income from Operations	23,266	20,388	15,348	43,655	31,037	69,918
	Less : Excise Duty & Sales Tax	1,633	1,404	898	3,037	1,778	3,992
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	21,634	18,984	14,450	40,618	29,258	65,926
	(b) Other Operating Income	8	3	2	8	6	610
	Total Income from operations (net)	21,840	18,987	14,452	40,626	29,264	66,536
2	Expenditure	13,085	12,025	9,141	25,111	18,495	38,414
	(a) Cost of materials consumed	2,387	1,839	2,113	4,325	3,883	7,336
	(b) Purchase of stock-in-trade	(648)	(1,012)	(1,412)	(1,660)	(2,224)	(92)
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	667	649	526	1,317	1,062	2,483
	(d) Employee benefits expense	640	632	504	1,273	986	2,422
	(e) Depreciation and Amortisation Expense	3,191	2,796	2,488	6,987	4,889	10,368
	(f) Other expenses	19,323	17,030	13,361	36,383	27,110	80,931
	Total expenses	2,317	1,957	1,082	4,273	2,154	5,605
3	Profit from Operations before Other Income, finance costs and exceptional items	1,967	1,082	1,082	4,273	2,154	5,605
4	Other Income	2,317	1,957	1,082	4,273	2,154	5,605
5	Profit from ordinary activities before finance cost and exceptional items	680	651	440	1,311	840	2,287
6	Finance costs (interest)	1,857	1,307	652	2,863	1,314	3,222
7	Profit from ordinary activities after finance cost but before Exceptional Items	1,657	1,307	652	2,863	1,314	876
8	Exceptional Items	495	419	156	914	360	800
9	Profit from Ordinary Activities before Tax	415	355	40	144	78	178
10	Tax Expenses (includes)	80	84	463	2,049	954	2,246
	Provision for Taxation	1,182	888	1,211	1,211	1,211	1,211
	Provision for Deferred Taxation	1,211	1,211	1,211	1,211	1,211	1,211
11	Net profit from ordinary Activities after Tax	1,211	1,211	1,211	1,211	1,211	1,211
13	Paid-up Equity Share Capital of Rs. 10/- each.						
14	Reserves & Surplus (excluding revaluation reserves)						
15	Earning per share (of Rs. 10 /- each) (not annualised)	9.59	7.33	4.07	16.92	7.89	17.84
	(a) Basic & Diluted	9.59	7.33	4.07	16.92	7.89	17.84

PART II

PARTICULARS OF SHAREHOLDING		30th Sept, 2012	30th June, 2012	30th Sept, 2011	30th Sept, 2012	30th Sept, 2011	31st Mar, 2012
1	Public shareholding	8,289,846	6,300,778	5,493,177	5,289,846	5,493,177	6,379,245
	- Number of Shares	43.62	43.78	45.37	43.62	45.37	44.43
	- Percentage of Total Shareholding						
2	Promoters & Promoter Group shareholding	Nil	Nil	Nil	Nil	Nil	Nil
a)	Pledged/Encumbered	Nil	Nil	Nil	Nil	Nil	Nil
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total Shareholding of the company)	6,838,805	6,807,177	6,815,373	6,838,805	6,815,373	6,729,306
	- Percentage of shares (as a % of the total Share capital of the company)	100	100	100	100	100	100
b)	Non-encumbered	100	100	100	100	100	100
	- Number of Shares	56.48	56.22	54.83	56.48	54.83	56.67
	- Percentage of shares (as a % of the total Shareholding of promoter and promoter group)						
	- Percentage of shares (as a % of the total Share capital of the company)						
		Qtr ended 30th Sept, 2012					
B	INVESTOR COMPLAINTS	0					
	Pending at the beginning of the quarter	3					
	Received during the quarter	3					
	Disposed of during the quarter	0					
	Remaining unresolved at the end of the quarter	0					



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Slon (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2012			(Rs. in lacs)	
Particulars	For the year ended			
	30.09.2012	31.03.2012		
A EQUITY AND LIABILITIES				
1 Shareholder funds	1,211	1,211		
(a) Share Capital	18,083	16,437		
(b) Reserves and surplus				
	19,274	17,848		
A Sub - total - Shareholders's funds				
2 Non-current liabilities	5,986	6,892		
(a) Long - term borrowings	2,881	2,447		
(b) Deferred tax liabilities (net)	844	771		
(c) Other long - term liabilities	172	-		
(d) Long - term provisions	8,894	9,911		
B Sub - total - Non - current liabilities				
3 Current liabilities	22,813	20,557		
(a) Short - term borrowings	9,308	9,379		
(b) Trade payables	2,481	2,868		
(c) Other current liabilities	1,532	902		
(d) Short - term provisions	38,136	33,703		
C Sub - total - current liabilities				
TOTAL - EQUITY AND LIABILITIES	65,004	61,262		
B ASSETS				
1 Non-current assets	28,538	27,653		
(a) Fixed assets (including CWIP)	692	692		
(b) Non - current investments	133	227		
(c) Long - term loans and advances				
Sub - total - Non - current assets	29,363	28,571		
2 Current assets	12,084	9,791		
(a) Inventories	19,363	18,060		
(b) Trade receivables	662	494		
(c) Cash and cash equivalents	1,970	2,715		
(d) Short - term loans and advances	1,562	1,630		
(e) Other - current assets	35,641	32,691		
Sub - total - current assets				
TOTAL - ASSETS	65,004	61,262		

Notes :

- The above results for the quarter and half year ended 30th September, 2012 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31st October, 2012.
- The Board of Directors have declared interim dividend of Rs.3.00 per Equity Shares of Rs. 10/- each (30 %) amounting to Rs.3,83,25,650 and 8th November, 2012 has been fixed as record date for the payment of the said interim dividend.
- Company is operating as a Single Segment Company engaged in Pharmaceuticals Business.
- Figures for the quarter ended 30th September, 2011 do not reflect effect of Amalgamation of Erstwhile Suyash Laboratories Limited with the Company and to that extent they are not comparable.
- Figures for the previous period have been regrouped and rearranged wherever necessary

For and on behalf of the Board
For AARTI DRUGS LIMITED

MR. HARSHIT M. SAVLA
(J.T. MANAGING DIRECTOR)

Place : Mumbai
Date: 31st October, 2012